Madrigal Pharmaceuticals, Inc. (MDGL) News

Madrigal Pharmaceuticals, Inc. (MDGL): $115.44

-1.58 (-1.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MDGL News Items

MDGL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com

Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | March 4, 2021

Madrigal Pharmaceuticals Earnings and Growth Analysis : Stock market Insights & financial analysis

Madrigal Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | February 23, 2021

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | January 12, 2021

Here's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 24, 2020

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

* Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET. * In the 100 mg open label arm of MAESTRO-NAFLD: * At week 16, MRI-PDFF (magnetic resonance imaging-proton density fat fraction) reduction compared to baseline was 53% overall (p<0.0001) and up to 62% in key subgroups * At weeks 12-24, statistically significant lowering of liver enzymes, inflammatory biomarkers and atherogenic lipids and lipoproteins were observed * At week 16, compared to baseline, a meaningful reduction (p=0.003) in magnetic resonance elastography (MRE), a measure of liver of fibrosis and inflammation was seenCONSHOHOCKEN, P...

Yahoo | November 13, 2020

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | November 12, 2020

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights - Stocks News Feed

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. The original target enrollment for MAESTRO… Read More »Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

Stocks News Feed | November 5, 2020

The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halo...

Benzinga | November 5, 2020

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Lowered by Zacks Investment Research

Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist […]

Dispatch Tribunal | October 24, 2020

The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ...

Benzinga | October 15, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6592 seconds.